drugset / Trial / NCT06595186
JK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM)
Non-randomizedSequentialOpen-labelTreatment
Summary
This study was designed to evaluate the safety, tolerability, efficacy and pharmacokinetics of JK-1201I combined with adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme after surgery and concomitant radio-chemotherapy.
Timeline
- Start
- 2022-10-31
- Primary completion
- 2026-08-16
- Completion
- 2026-12-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JK-1201I | Unknown | — | Intravenous |
| Background | Temozolomide | Small molecule | — | — |